HEADER HYDROLASE/HYDROLASE INHIBITOR 04-MAY-14 4QAG TITLE STRUCTURE OF A DIHYDROXYCOUMARIN ACTIVE-SITE INHIBITOR IN COMPLEX WITH TITLE 2 THE RNASE H DOMAIN OF HIV-1 REVERSE TRANSCRIPTASE COMPND MOL_ID: 1; COMPND 2 MOLECULE: REVERSE TRANSCRIPTASE/RIBONUCLEASE H; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 1024-1156; COMPND 5 SYNONYM: EXORIBONUCLEASE H, P66 RT; COMPND 6 EC: 2.7.7.49, 2.7.7.7, 3.1.26.13, 3.1.13.2; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; SOURCE 3 ORGANISM_COMMON: HIV-1; SOURCE 4 ORGANISM_TAXID: 11678; SOURCE 5 GENE: GAG-POL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PLYSS KEYWDS RNASE H INHIBITOR, STRUCTURE-BASED DRUG DESIGN, ACTIVE SITE, KEYWDS 2 TRANSFERASE, DIHYDROXYCOUMARIN ANALOGS, DIHYDROXY-BENZOPYRONE KEYWDS 3 DERIVATIVES, DIVALENT CATION CHELATOR, AIDS, REVERSE TRANSCRIPTASE, KEYWDS 4 PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR D.M.HIMMEL,W.C.HO,E.ARNOLD REVDAT 4 20-SEP-23 4QAG 1 REMARK LINK REVDAT 3 09-JUL-14 4QAG 1 JRNL REVDAT 2 25-JUN-14 4QAG 1 JRNL REVDAT 1 04-JUN-14 4QAG 0 SPRSDE 04-JUN-14 4QAG 4JE2 JRNL AUTH D.M.HIMMEL,N.S.MYSHAKINA,T.ILINA,A.VAN RY,W.C.HO, JRNL AUTH 2 M.A.PARNIAK,E.ARNOLD JRNL TITL STRUCTURE OF A DIHYDROXYCOUMARIN ACTIVE-SITE INHIBITOR IN JRNL TITL 2 COMPLEX WITH THE RNASE H DOMAIN OF HIV-1 REVERSE JRNL TITL 3 TRANSCRIPTASE AND STRUCTURE-ACTIVITY ANALYSIS OF INHIBITOR JRNL TITL 4 ANALOGS. JRNL REF J.MOL.BIOL. V. 426 2617 2014 JRNL REFN ISSN 0022-2836 JRNL PMID 24840303 JRNL DOI 10.1016/J.JMB.2014.05.006 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.M.HIMMEL,K.A.MAEGLEY,T.A.PAULY,J.D.BAUMAN,K.DAS,C.DHARIA, REMARK 1 AUTH 2 A.D.CLARK JR.,K.RYAN,M.J.HICKEY,R.A.LOVE,S.H.HUGHES, REMARK 1 AUTH 3 S.BERGQVIST,E.ARNOLD REMARK 1 TITL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE WITH THE INHIBITOR REMARK 1 TITL 2 BETA-THUJAPLICINOL BOUND AT THE RNASE H ACTIVE SITE REMARK 1 REF STRUCTURE V. 17 1625 2009 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 2 REMARK 1 AUTH S.CHUNG,D.M.HIMMEL,J.JIANG,K.WOJTAK,J.D.BAUMAN,J.W.RAUSCH, REMARK 1 AUTH 2 J.A.WILSON,J.A.BEUTLER,C.J.THOMAS,E.ARNOLD,S.F.J.LE GRICE REMARK 1 TITL SYNTHESIS, ACTIVITY, AND STRUCTURAL ANALYSIS OF NOVEL REMARK 1 TITL 2 ALPHA-HYDROXYTROPOLONE INHIBITORS OF HUMAN IMMUNODEFICIENCY REMARK 1 TITL 3 VIRUS REVERSE TRANSCRIPTASE-ASSOCIATED RIBONUCLEASE H REMARK 1 REF J.MED.CHEM. V. 54 4462 2011 REMARK 1 REFN ISSN 0022-2623 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.DAS,J.D.BAUMAN,A.D.CLARK JR.,Y.V.FRENKEL,P.J.LEWI, REMARK 1 AUTH 2 A.J.SHATKIN,S.H.HUGHES,E.ARNOLD REMARK 1 TITL HIGH-RESOLUTION STRUCTURES OF HIV-1 REVERSE REMARK 1 TITL 2 TRANSCRIPTASE/TMC278 COMPLEXES: STRATEGIC FLEXIBILITY REMARK 1 TITL 3 EXPLAINS POTENCY AGAINST RESISTANCE MUTATIONS REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 105 1466 2008 REMARK 1 REFN ISSN 0027-8424 REMARK 1 REFERENCE 4 REMARK 1 AUTH D.M.HIMMEL,S.G.SARAFIANOS,S.DHARMASENA,M.M.HOSSAIN, REMARK 1 AUTH 2 K.MCCOY-SIMANDLE,T.ILINA,A.D.CLARK JR.,J.L.KNIGHT, REMARK 1 AUTH 3 J.G.JULIAS,P.K.CLARK,K.KROGH-JESPERSEN,R.M.LEVY,S.H.HUGHES, REMARK 1 AUTH 4 M.A.PARNIAK,E.ARNOLD REMARK 1 TITL HIV-1 REVERSE TRANSCRIPTASE STRUCTURE WITH RNASE H INHIBITOR REMARK 1 TITL 2 DIHYDROXY BENZOYL NAPHTHYL HYDRAZONE BOUND AT A NOVEL SITE REMARK 1 REF ACS CHEM.BIOL. V. 1 702 2006 REMARK 1 REFN ISSN 1554-8929 REMARK 2 REMARK 2 RESOLUTION. 1.71 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.8_1066 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.71 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.57 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.3 REMARK 3 NUMBER OF REFLECTIONS : 34739 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.183 REMARK 3 R VALUE (WORKING SET) : 0.182 REMARK 3 FREE R VALUE : 0.190 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 2.720 REMARK 3 FREE R VALUE TEST SET COUNT : 946 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 28.5691 - 3.2734 1.00 4893 150 0.1629 0.1703 REMARK 3 2 3.2734 - 2.5988 1.00 4920 125 0.1936 0.1907 REMARK 3 3 2.5988 - 2.2704 1.00 4898 125 0.1784 0.2032 REMARK 3 4 2.2704 - 2.0629 1.00 4899 134 0.1731 0.1822 REMARK 3 5 2.0629 - 1.9151 0.99 4910 144 0.2055 0.2133 REMARK 3 6 1.9151 - 1.8022 0.99 4831 146 0.2731 0.2847 REMARK 3 7 1.8022 - 1.7120 0.91 4442 122 0.3710 0.4403 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.230 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 26.880 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 34.34 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 56.69 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.008 2158 REMARK 3 ANGLE : 0.942 2930 REMARK 3 CHIRALITY : 0.055 330 REMARK 3 PLANARITY : 0.003 372 REMARK 3 DIHEDRAL : 15.122 798 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4QAG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-MAY-14. REMARK 100 THE DEPOSITION ID IS D_1000085807. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-JUN-10 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 8.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X25 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.10 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 34856 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.710 REMARK 200 RESOLUTION RANGE LOW (A) : 40.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -0.400 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.5 REMARK 200 DATA REDUNDANCY : 7.800 REMARK 200 R MERGE (I) : 0.08800 REMARK 200 R SYM (I) : 0.08800 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 27.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.71 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.77 REMARK 200 COMPLETENESS FOR SHELL (%) : 89.5 REMARK 200 DATA REDUNDANCY IN SHELL : 2.90 REMARK 200 R MERGE FOR SHELL (I) : 0.45100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER 2.1.4 REMARK 200 STARTING MODEL: PDB ENTRY 3IG1 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.27 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.88 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM BICINE PH 8.2, 10 MM MANGANESE REMARK 280 SULFATE, 1 MM SODIUM AZIDE, 9% PEG 3350, COMBINED WITH EQUAL REMARK 280 VOLUME OF 10 MM TRIS PH 8.0, 75 MM NACL, 20 MG/ML (1.34 MM) REMARK 280 RNASE H, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 37.36667 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 74.73333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1690 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13860 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 TRP A 426 TYR A 427 104.28 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MN A 601 MN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 443 OD1 REMARK 620 2 ASP A 549 OD1 97.5 REMARK 620 3 F95 A 603 O1 100.7 161.8 REMARK 620 4 F95 A 603 O2 177.2 81.8 80.1 REMARK 620 5 HOH A 711 O 89.9 91.9 87.7 92.8 REMARK 620 6 HOH A 712 O 90.1 91.2 89.3 87.2 176.9 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MN A 602 MN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 443 OD2 REMARK 620 2 GLU A 478 OE2 94.5 REMARK 620 3 ASP A 498 OD1 116.8 103.3 REMARK 620 4 ASP A 498 OD2 84.9 157.1 57.7 REMARK 620 5 F95 A 603 O1 89.5 116.0 130.8 86.9 REMARK 620 6 F95 A 603 O3 162.1 85.7 80.4 101.8 74.5 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MN B 601 MN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP B 443 OD1 REMARK 620 2 ASP B 549 OD1 99.1 REMARK 620 3 F95 B 603 O1 98.4 162.5 REMARK 620 4 F95 B 603 O2 178.1 82.4 80.2 REMARK 620 5 HOH B 705 O 85.6 89.9 89.5 93.3 REMARK 620 6 HOH B 717 O 93.1 89.1 91.9 88.1 178.2 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MN B 602 MN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP B 443 OD2 REMARK 620 2 GLU B 478 OE1 87.8 REMARK 620 3 ASP B 498 OD1 121.8 97.3 REMARK 620 4 ASP B 498 OD2 92.7 151.8 58.8 REMARK 620 5 F95 B 603 O1 93.8 110.3 135.9 97.8 REMARK 620 6 F95 B 603 O3 158.9 81.5 77.9 105.3 73.1 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MN A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MN A 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE F95 A 603 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MN B 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MN B 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE F95 B 603 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3K2P RELATED DB: PDB REMARK 900 HIV-1 RNASE H DOMAIN IN COMPLEX WITH BETA-THUJAPLICINOL, AN ACTIVE REMARK 900 SITE RNASE H INHIBITOR REMARK 900 RELATED ID: 3IG1 RELATED DB: PDB REMARK 900 FULL-LENGTH HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BETA- REMARK 900 THUJAPLICINOL, AN ACTIVE SITE RNASE H INHIBITOR REMARK 900 RELATED ID: 3QLH RELATED DB: PDB REMARK 900 FULL-LENGTH HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TMC278 REMARK 900 (RILPIVIRINE) AND MANICOL REMARK 900 RELATED ID: 3IFJ RELATED DB: PDB REMARK 900 FULL-LENGTH HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DHBNH, AN REMARK 900 ALLOSTERIC RNASE H INHIBITOR REMARK 900 RELATED ID: 4G1Q RELATED DB: PDB REMARK 900 FULL-LENGTH HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH TMC278 REMARK 900 (RILPIVIRINE, EDURANT)) DBREF 4QAG A 425 557 UNP P03366 POL_HV1B1 1024 1156 DBREF 4QAG B 425 557 UNP P03366 POL_HV1B1 1024 1156 SEQRES 1 A 133 LEU TRP TYR GLN LEU GLU LYS GLU PRO ILE VAL GLY ALA SEQRES 2 A 133 GLU THR PHE TYR VAL ASP GLY ALA ALA ASN ARG GLU THR SEQRES 3 A 133 LYS LEU GLY LYS ALA GLY TYR VAL THR ASN LYS GLY ARG SEQRES 4 A 133 GLN LYS VAL VAL PRO LEU THR ASN THR THR ASN GLN LYS SEQRES 5 A 133 THR GLU LEU GLN ALA ILE TYR LEU ALA LEU GLN ASP SER SEQRES 6 A 133 GLY LEU GLU VAL ASN ILE VAL THR ASP SER GLN TYR ALA SEQRES 7 A 133 LEU GLY ILE ILE GLN ALA GLN PRO ASP LYS SER GLU SER SEQRES 8 A 133 GLU LEU VAL ASN GLN ILE ILE GLU GLN LEU ILE LYS LYS SEQRES 9 A 133 GLU LYS VAL TYR LEU ALA TRP VAL PRO ALA HIS LYS GLY SEQRES 10 A 133 ILE GLY GLY ASN GLU GLN VAL ASP LYS LEU VAL SER ALA SEQRES 11 A 133 GLY ILE ARG SEQRES 1 B 133 LEU TRP TYR GLN LEU GLU LYS GLU PRO ILE VAL GLY ALA SEQRES 2 B 133 GLU THR PHE TYR VAL ASP GLY ALA ALA ASN ARG GLU THR SEQRES 3 B 133 LYS LEU GLY LYS ALA GLY TYR VAL THR ASN LYS GLY ARG SEQRES 4 B 133 GLN LYS VAL VAL PRO LEU THR ASN THR THR ASN GLN LYS SEQRES 5 B 133 THR GLU LEU GLN ALA ILE TYR LEU ALA LEU GLN ASP SER SEQRES 6 B 133 GLY LEU GLU VAL ASN ILE VAL THR ASP SER GLN TYR ALA SEQRES 7 B 133 LEU GLY ILE ILE GLN ALA GLN PRO ASP LYS SER GLU SER SEQRES 8 B 133 GLU LEU VAL ASN GLN ILE ILE GLU GLN LEU ILE LYS LYS SEQRES 9 B 133 GLU LYS VAL TYR LEU ALA TRP VAL PRO ALA HIS LYS GLY SEQRES 10 B 133 ILE GLY GLY ASN GLU GLN VAL ASP LYS LEU VAL SER ALA SEQRES 11 B 133 GLY ILE ARG HET MN A 601 1 HET MN A 602 1 HET F95 A 603 17 HET MN B 601 1 HET MN B 602 1 HET F95 B 603 17 HETNAM MN MANGANESE (II) ION HETNAM F95 (7,8-DIHYDROXY-2-OXO-2H-CHROMEN-4-YL)ACETIC ACID FORMUL 3 MN 4(MN 2+) FORMUL 5 F95 2(C11 H8 O6) FORMUL 9 HOH *176(H2 O) HELIX 1 1 THR A 473 SER A 489 1 17 HELIX 2 2 SER A 499 ALA A 508 1 10 HELIX 3 3 SER A 515 LYS A 528 1 14 HELIX 4 4 ILE A 542 ALA A 554 1 13 HELIX 5 5 THR B 473 SER B 489 1 17 HELIX 6 6 SER B 499 ALA B 508 1 10 HELIX 7 7 SER B 515 LYS B 528 1 14 HELIX 8 8 ILE B 542 ALA B 554 1 13 SHEET 1 A 5 GLN A 464 LEU A 469 0 SHEET 2 A 5 GLY A 453 THR A 459 -1 N ALA A 455 O VAL A 467 SHEET 3 A 5 THR A 439 ALA A 446 -1 N TYR A 441 O VAL A 458 SHEET 4 A 5 GLU A 492 THR A 497 1 O ASN A 494 N PHE A 440 SHEET 5 A 5 LYS A 530 TRP A 535 1 O ALA A 534 N ILE A 495 SHEET 1 B 5 GLN B 464 LEU B 469 0 SHEET 2 B 5 GLY B 453 THR B 459 -1 N GLY B 453 O LEU B 469 SHEET 3 B 5 THR B 439 ALA B 446 -1 N TYR B 441 O VAL B 458 SHEET 4 B 5 GLU B 492 THR B 497 1 O ASN B 494 N PHE B 440 SHEET 5 B 5 LYS B 530 TRP B 535 1 O TYR B 532 N ILE B 495 LINK OD1 ASP A 443 MN MN A 601 1555 1555 2.21 LINK OD2 ASP A 443 MN MN A 602 1555 1555 2.09 LINK OE2 GLU A 478 MN MN A 602 1555 1555 2.08 LINK OD1 ASP A 498 MN MN A 602 1555 1555 2.07 LINK OD2 ASP A 498 MN MN A 602 1555 1555 2.34 LINK OD1 ASP A 549 MN MN A 601 1555 1555 2.14 LINK MN MN A 601 O1 F95 A 603 1555 1555 1.99 LINK MN MN A 601 O2 F95 A 603 1555 1555 2.22 LINK MN MN A 601 O HOH A 711 1555 1555 2.19 LINK MN MN A 601 O HOH A 712 1555 1555 2.21 LINK MN MN A 602 O1 F95 A 603 1555 1555 2.13 LINK MN MN A 602 O3 F95 A 603 1555 1555 2.49 LINK OD1 ASP B 443 MN MN B 601 1555 1555 2.19 LINK OD2 ASP B 443 MN MN B 602 1555 1555 2.11 LINK OE1 GLU B 478 MN MN B 602 1555 1555 2.14 LINK OD1 ASP B 498 MN MN B 602 1555 1555 2.08 LINK OD2 ASP B 498 MN MN B 602 1555 1555 2.29 LINK OD1 ASP B 549 MN MN B 601 1555 1555 2.12 LINK MN MN B 601 O1 F95 B 603 1555 1555 2.14 LINK MN MN B 601 O2 F95 B 603 1555 1555 2.22 LINK MN MN B 601 O HOH B 705 1555 1555 2.20 LINK MN MN B 601 O HOH B 717 1555 1555 2.19 LINK MN MN B 602 O1 F95 B 603 1555 1555 1.99 LINK MN MN B 602 O3 F95 B 603 1555 1555 2.55 SITE 1 AC1 6 ASP A 443 ASP A 549 MN A 602 F95 A 603 SITE 2 AC1 6 HOH A 711 HOH A 712 SITE 1 AC2 5 ASP A 443 GLU A 478 ASP A 498 MN A 601 SITE 2 AC2 5 F95 A 603 SITE 1 AC3 12 ASP A 443 GLU A 478 ASP A 498 SER A 499 SITE 2 AC3 12 HIS A 539 ASP A 549 MN A 601 MN A 602 SITE 3 AC3 12 HOH A 711 HOH A 712 HOH A 721 HOH A 780 SITE 1 AC4 6 ASP B 443 ASP B 549 MN B 602 F95 B 603 SITE 2 AC4 6 HOH B 705 HOH B 717 SITE 1 AC5 5 ASP B 443 GLU B 478 ASP B 498 MN B 601 SITE 2 AC5 5 F95 B 603 SITE 1 AC6 13 ASP B 443 GLU B 478 ASP B 498 SER B 499 SITE 2 AC6 13 HIS B 539 ASP B 549 MN B 601 MN B 602 SITE 3 AC6 13 HOH B 703 HOH B 705 HOH B 706 HOH B 717 SITE 4 AC6 13 HOH B 718 CRYST1 51.164 51.164 112.100 90.00 90.00 120.00 P 31 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019545 0.011284 0.000000 0.00000 SCALE2 0.000000 0.022569 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008921 0.00000